Valuation metrics in some sectors do appear substantially stretched-particularly those for smaller firms in the social media and biotechnology industries Some analysts have reacted to this by claiming that there is no price-to-earnings ratio in small cap biotechs. The issue is that excessive pricing in the biotech industry doesn't seem limited to small caps, and that indeed there is a ratio.